Classifications: antineoplastic; hormone; anabolic steroid
Pregnancy Category: C
Controlled Substance: Schedule III
50 mg tablets
Chemotherapeutic agent with chemical configuration similar to certain androgens but devoid of androgenic activity (virilization)
in therapeutic doses. Exact mechanism of antineoplastic action unknown.
In breast cancer, effect may result from depression of ovarian function by inhibition of synthesis of pituitary gonadotropin.
Indicated by decrease in size of tumor; more than 50% of nonosseous lesions decrease in size even though all bone lesions
Adjunctive treatment in palliation of breast carcinoma in postmenopausal women when hormone therapy is indicated. Also effective
in women diagnosed before menopause in whom ovarian function has been subsequently terminated.
Premenopausal women; breast cancer in males. Pregnancy (category C), lactation.
Hypercalcemia; cardiorenal disease.
|Adjunctive Therapy for Breast Cancer
Adult: PO 250 mg q.i.d.
CNS: Paresthesias. Endocrine: Deepening of the voice, acne, facial hair growth, clitoral enlargement. GI: Glossitis, anorexia; nausea, vomiting. CV: Hypertension, edema in extremities.
- Note: If anticoagulants are concurrently ordered, dose is usually reduced when testolactone is initiated.
- Store at 15°30° C (59°86° F) unless otherwise directed. Protect from freezing.
Urinary 17-OHCS determinations may be elevated.
Drug: May enhance hypoprothrombinemic effects of oral anticoagulants.
Absorption: Readily absorbed from GI tract. Metabolism: Metabolized in liver. Elimination: Excreted in urine.
Assessment & Drug Effects
- Monitor therapeutic effectiveness. Clinical response usually occurs in 612 wk.
- Lab tests: Check plasma calcium levels periodically (normal serum calcium: 8.510.6 mg/dL).
- Monitor PT and INR carefully with concurrent anticoagulant therapy.
- Report S&S that suggest impending hypercalcemia (see Appendix F).
- Monitor I&O ratio and pattern.
- Encourage patient mobility if feasible; if not, assist with passive exercises.
Patient & Family Education
- Drug treatment is usually continued for a minimum of 3 mo to evaluate response (unless there is active progression of the
- Be aware that hypercalcemia represents active remission of bone metastasis; if it occurs, appropriate therapy is instituted.
- Do not breast feed while taking this drug.